专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110112052A1 SPIRO-OXINDOLE MDM2 ANTAGONISTS 失效
公开(公告)号：US20110112052A1
公开(公告)日：2011-05-12
申请号：US12945511
申请日：2010-11-12
申请人： Shaomeng Wang , Shanghai Yu , Wei Sun , Sanjeev Kumar Shangary , Duxin Sun , Peng Zou , Donna McEachern , Yujun Zhao
发明人： Shaomeng Wang , Shanghai Yu , Wei Sun , Sanjeev Kumar Shangary , Duxin Sun , Peng Zou , Donna McEachern , Yujun Zhao
IPC分类号： C07D487/10 , A61K31/407 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/675 , A61P1/00 , A61P35/04
CPC分类号： C07D487/10 , A61K31/407 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/675 , A61K45/06 , C07D471/20 , C07D491/107 , C07D495/10 , C07F9/6561 , A61K2300/00
摘要： Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.
摘要翻译：本文提供了药物化学领域中的化合物，组合物和方法。本文提供的化合物和组合物涉及作为p53和MDM2之间的相互作用的拮抗剂的螺 - 羟吲哚，以及它们作为治疗癌症和其它疾病的治疗剂的用途。

2. 发明授权

US08518984B2 Spiro-oxindole MDM2 antagonists 失效
公开(公告)号：US08518984B2
公开(公告)日：2013-08-27
申请号：US12945511
申请日：2010-11-12
申请人： Shaomeng Wang , Shanghai Yu , Wei Sun , Sanjeev Kumar , Duxin Sun , Peng Zou , Donna McEachern , Yujun Zhao
发明人： Shaomeng Wang , Shanghai Yu , Wei Sun , Sanjeev Kumar , Duxin Sun , Peng Zou , Donna McEachern , Yujun Zhao
IPC分类号： C07D487/10 , A61K31/4015
CPC分类号： C07D487/10 , A61K31/407 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/675 , A61K45/06 , C07D471/20 , C07D491/107 , C07D495/10 , C07F9/6561 , A61K2300/00
摘要： Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.

3. 发明授权

US08691184B2 Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same 有权
标题翻译： Bcl-2 / Bcl-xL抑制剂和使用其的治疗方法
公开(公告)号：US08691184B2
公开(公告)日：2014-04-08
申请号：US13356763
申请日：2012-01-24
申请人： Shaomeng Wang , Haibin Zhou , Jianfang Chen , Angelo Aguilar , Jennifer L. Meagher , Duxin Sun , Chao-Yie Yang , Liu Liu , Longchuan Bai , Donna McEachem , Jeanne Stuckey , Xiaoqin Li
发明人： Shaomeng Wang , Haibin Zhou , Jianfang Chen , Angelo Aguilar , Jennifer L. Meagher , Duxin Sun , Chao-Yie Yang , Liu Liu , Longchuan Bai , Donna McEachem , Jeanne Stuckey , Xiaoqin Li
IPC分类号： A61K51/00 , A61K31/5377 , A61K31/496 , C07D413/14 , C07D403/12 , C07D401/14 , C07D403/10 , C07D405/10 , A61P35/00 , A61K31/5513 , C07D471/04
CPC分类号： C07D239/28 , C07D207/34 , C07D231/12 , C07D233/28 , C07D233/56 , C07D261/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D471/04
摘要： Inhibitors of Bcl-2/Bcl-xL and compositions containing the same are disclosed. Methods of using the Bcl-2/Bcl-xL inhibitors in the treatment of diseases and conditions wherein inhibition of Bcl-2/Bcl-xL provides a benefit, like cancers, also are disclosed.
摘要翻译：公开了Bcl-2 / Bcl-xL的抑制剂及其组合物。还公开了使用Bcl-2 / Bcl-xL抑制剂治疗其中Bcl-2 / Bcl-xL的抑制提供益处的疾病和病症的方法，如癌症。

4. 发明申请

US20120189539A1 BCL-2/BCL-XL INHIBITORS AND THERAPEUTIC METHODS USING THE SAME 有权
标题翻译： BCL-2 / BCL-XL抑制剂及其治疗方法
公开(公告)号：US20120189539A1
公开(公告)日：2012-07-26
申请号：US13356763
申请日：2012-01-24
申请人： Shaomeng Wang , Haibin Zhou , Jianfang Chen , Angelo Aguilar , Jennifer L. Meagher , Duxin Sun , Chao-Yie Yang , Liu Liu , Longchuan Bai , Donna McEachem , Jeanne Stuckey , Xiaoqin Li
发明人： Shaomeng Wang , Haibin Zhou , Jianfang Chen , Angelo Aguilar , Jennifer L. Meagher , Duxin Sun , Chao-Yie Yang , Liu Liu , Longchuan Bai , Donna McEachem , Jeanne Stuckey , Xiaoqin Li
IPC分类号： A61K51/00 , A61K31/5377 , A61K31/496 , C07D413/14 , C07D403/12 , C07D401/14 , C07D403/10 , C07D405/10 , A61P35/00 , A61K31/5513 , C07D471/04
CPC分类号： C07D239/28 , C07D207/34 , C07D231/12 , C07D233/28 , C07D233/56 , C07D261/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D471/04
摘要： Inhibitors of Bcl-2/Bcl-xL and compositions containing the same are disclosed. Methods of using the Bcl-2/Bcl-xL inhibitors in the treatment of diseases and conditions wherein inhibition of Bcl-2/Bcl-xL provides a benefit, like cancers, also are disclosed.
摘要翻译：公开了Bcl-2 / Bcl-xL的抑制剂及其组合物。还公开了使用Bcl-2 / Bcl-xL抑制剂治疗其中Bcl-2 / Bcl-xL的抑制提供益处的疾病和病症的方法，如癌症。

5. 发明申请

US20120035457A1 ELECTROMAGNETIC SYSTEM AND METHOD 审中-公开
标题翻译：电磁系统与方法
公开(公告)号：US20120035457A1
公开(公告)日：2012-02-09
申请号：US13210293
申请日：2011-08-15
申请人： Vishwanath Subramaniam , Joseph West , Jennifer McFerran Brock , Emily Sequin , Duxin Sun , Peng Zou
发明人： Vishwanath Subramaniam , Joseph West , Jennifer McFerran Brock , Emily Sequin , Duxin Sun , Peng Zou
IPC分类号： A61B5/053 , A61B5/05 , A61N2/02
CPC分类号： A61B5/05 , A61B5/415 , A61B5/418
摘要： Differences of electromagnetic (EM) properties between healthy and cancerous tissues allow detection of abnormal conditions occurring in a tissue of an animal, for example, intra-operative cancer detection. By using a time-varying EM field, electrical eddy currents are generated in the tissue sample, and assessed using phase-sensitive detection. In some aspects, a change in phase shift between the voltage in a receiver coil and the voltage in a driver coil provide a direct and immediate indication of differences in EM properties of specimens.
摘要翻译：健康和癌组织之间的电磁（EM）特性的差异允许检测动物组织中发生的异常状况，例如手术前癌症检测。通过使用时变EM场，在组织样品中产生电涡流，并使用相敏检测进行评估。在一些方面，接收器线圈中的电压和驱动器线圈中的电压之间的相移的变化提供了样品的EM性质的差异的直接和即时的指示。

6. 发明申请

US20090234225A1 FLUORESCENCE DETECTION SYSTEM 审中-公开
标题翻译：荧光检测系统
公开(公告)号：US20090234225A1
公开(公告)日：2009-09-17
申请号：US12352408
申请日：2009-01-12
申请人： Edward W. Martin , Ronald X. Xu , Duxin Sun , Stephen P. Povoski , Joseph Pierre Heremans , Robert Lee , Vish V. Subramaniam , Claudia Turro
发明人： Edward W. Martin , Ronald X. Xu , Duxin Sun , Stephen P. Povoski , Joseph Pierre Heremans , Robert Lee , Vish V. Subramaniam , Claudia Turro
IPC分类号： A61B6/00 , A61K49/00
CPC分类号： G01N21/6456 , G01N21/6428 , G01N33/57469 , G01N33/582
摘要： Exemplary embodiments include systems, methods, and compositions for the intra-operative detection of target tissue. At least one embodiment includes a fluorescence detection instrument that may be used for intra-operative detection of a fluorescent targeting agent, its binding site, and its interaction within cancer tissues. An exemplary embodiment is highly sensitive to the local deposition of fluorescence agents even at a low concentration. In at least one embodiment, the system includes a handheld navigation instrument that is usable to excite, detect, and report the fluorescent deposition of the targeting agent in real-time. In alternative embodiments, the system includes a wearable unit to excite, detect, and visually report the fluorescent deposition of the targeting agent to the user. The wearable unit includes eyewear that allow the user to perform image-guided surgery based on the near real-time fluorescence detection of the fluorescent targeting agent.
摘要翻译：示例性实施方案包括用于目标组织的术中检测的系统，方法和组合物。至少一个实施方案包括可用于术中检测荧光靶向剂，其结合位点及其在癌组织内的相互作用的荧光检测仪器。一个示例性实施方案即使在低浓度下也对荧光剂的局部沉积高度敏感。在至少一个实施例中，该系统包括可用于实时地激发，检测和报告靶向剂的荧光沉积的手持式导航仪器。在替代实施例中，系统包括可佩戴单元，以激发，检测和视觉报告目标剂对用户的荧光沉积。可穿戴单元包括允许用户基于荧光靶向剂的近实时荧光检测来执行图像引导手术的眼镜。

7. 发明申请

US20050059719A1 Solid dosage formulation containing a Factor Xa inhibitor and method 审中-公开
标题翻译：含有因子Xa抑制剂和方法的固体剂量制剂
公开(公告)号：US20050059719A1
公开(公告)日：2005-03-17
申请号：US10924043
申请日：2004-08-23
申请人： Sherif Badawy , Munir Hussain , Duxin Sun
发明人： Sherif Badawy , Munir Hussain , Duxin Sun
IPC分类号： A61K9/20 , A61K31/42
CPC分类号： A61K9/2054 , A61K31/42
摘要： An oral solid dosage formulation is provided which contains a Factor Xa inhibitor for which oral bioavailability is not reduced by co-administration of antacids, H2 antagonists and proton pump inhibitors. Such solid dosage formulation includes the Factor Xa inhibitor of the structure, a pharmaceutically acceptable carrier, and an acid component, such as tartaric acid, whereby upon ingestion of the oral solid dosage formulation, the acid component increases solubility of the Factor Xa inhibitor in the local environment of the dissolving solid dosage formulation resulting in an otherwise lower degree of supersaturation of the Factor Xa inhibitor in such environment, than if the acid were not present. The result is that precipitation of the Factor Xa inhibitor in the form of its insoluble free base is minimized during dissolution of the Factor Xa inhibitor thereby increasing its oral bioavailability. A method for enhancing bioavailability of the Factor Xa inhibitor is also provided wherein an acid such as tartaric acid is incorporated with the solid dosage pharmaceutical carrier for the Factor Xa inhibitor.
摘要翻译：提供口服固体剂量制剂，其含有通过共同给予抗酸剂，H 2拮抗剂和质子泵抑制剂而不降低口服生物利用度的因子Xa抑制剂。这种固体剂量制剂包括结构的因子Xa抑制剂，药学上可接受的载体和酸组分，例如酒石酸，由此，在摄取口服固体剂量制剂后，酸组分增加因子Xa抑制剂在溶解固体剂量制剂的局部环境导致因素Xa抑制剂在这种环境中的过饱和程度低于不存在酸的情况。结果是在因子Xa抑制剂的溶解过程中，其不溶性游离碱形式的因子Xa抑制剂的沉淀被最小化，从而增加其口服生物利用度。还提供了用于提高因子Xa抑制剂的生物利用度的方法，其中将诸如酒石酸的酸与用于因子Xa抑制剂的固体剂量药物载体结合。

8. 发明申请

US20100249231A1 HSP90 Inhibitors of Protein-Protein Interaction HSP90 Chaperone Complexes and Therapeutic Uses Thereof 审中-公开
标题翻译： HSP90蛋白 - 蛋白质相互作用的抑制剂HSP90伴侣配合物及其治疗用途
公开(公告)号：US20100249231A1
公开(公告)日：2010-09-30
申请号：US12741430
申请日：2008-11-10
申请人： Duxin Sun , Tao Zhang
发明人： Duxin Sun , Tao Zhang
IPC分类号： A61K31/19 , C12N5/02 , C07C59/00 , C12Q1/02
CPC分类号： A61K31/20 , G01N33/57438 , G01N2500/10
摘要： A novel Hsp90 inhibitor that disrupts protein-protein interaction in a Hsp90 superchaperone complex without blocking ATP binding and methods for treating diseases such as pancreatic cancer are disclosed.
摘要翻译：公开了一种破坏Hsp90超级互补蛋白复合体中蛋白质 - 蛋白质相互作用而不阻断ATP结合的新型Hsp90抑制剂和用于治疗疾病如胰腺癌的方法。

9. 发明申请

US20080312162A1 Methods and Compositions for Enzyme-Specific Activation of Carbohydrate-Conjugated Prodrugs 审中-公开
标题翻译：碳水化合物共轭前体的酶特异性活化的方法和组合物
公开(公告)号：US20080312162A1
公开(公告)日：2008-12-18
申请号：US11664034
申请日：2005-10-07
申请人： Duxin Sun , Peng George Wang , Edward Martin, JR.
发明人： Duxin Sun , Peng George Wang , Edward Martin, JR.
IPC分类号： A61K31/70 , A61P35/04
CPC分类号： A61K31/7024
摘要： Methods for the targeted activation of prodrugs by enzymes, which cleave a linkage between a carbohydrate conjugate and a drug. Means to target the activation of prodrugs to specific cells by linking the enzyme to an antibody molecule. Carbohydrate conjugates of geldanamycin.
摘要翻译：用于通过切割碳水化合物缀合物和药物之间的连接的酶靶向激活前药的方法。通过将酶与抗体分子连接来靶向前药向特定细胞的活化的手段。格尔德霉素的碳水化合物缀合物。

10. 发明授权

US07737123B2 Multidrug resistant anticancer anthracyclines 有权
标题翻译：多药耐药蒽环类抗生素
公开(公告)号：US07737123B2
公开(公告)日：2010-06-15
申请号：US11432901
申请日：2006-05-12
申请人： Guisheng Zhang , Lanyan Fang , Peng George Wang , Duxin Sun
发明人： Guisheng Zhang , Lanyan Fang , Peng George Wang , Duxin Sun
IPC分类号： A61K31/70 , C07H15/24
CPC分类号： C07H15/252 , C07H15/24 , C07H19/056
摘要： Daunorubicin (“DNR”) compounds synthesized with uncommon sugars exhibit enhanced effectiveness in treating various drug-resistant cancers.
摘要翻译：用不常见的糖合成的柔红霉素（“DNR”）化合物在治疗各种耐药性癌症方面表现出增强的有效性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式